Kiniksa Pharmaceuticals International (KNSA) Amortizatization of Intangibles (2018 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Amortizatization of Intangibles came in at -$93000.0 in Q2 2026, down 111.02% on a YoY basis from $844000.0 in Q2 2025, and up 92.86% quarter-over-quarter from -$1.3 million in Q1 2026.
Powered by 
Analysis
Kiniksa Pharmaceuticals International (KNSA) Amortizatization of Intangibles (2018 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has reported Amortizatization of Intangibles for 9 consecutive years, with -$93000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Amortizatization of Intangibles fell 111.02% year-over-year to -$93000.0; the trailing twelve-month figure through Jun 2026 stood at -$1.1 million (down 515.56% YoY), and the FY2025 full-year result was $916000.0, up 307.71% from the prior year.
- Amortizatization of Intangibles grew to -$93000.0 in Q2 2026 per KNSA's latest filing, from -$1.3 million in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $1.2 million in Q2 2023 and bottomed at -$1.4 million in Q3 2023.
- Historically, Amortizatization of Intangibles has averaged $12777.8 across 5 years, with a median of $21500.0 in 2022.
- The widest YoY moves for Amortizatization of Intangibles: up 1615.79% in 2023, down 1310.92% in 2023.
- Over 5 years, Amortizatization of Intangibles stood at $203000.0 in 2022, then jumped by 45.81% to $296000.0 in 2023, then sank by 376.69% to -$819000.0 in 2024, then soared by 213.55% to $930000.0 in 2025, then sank by 110.0% to -$93000.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered -$93000.0, -$1.3 million, and $930000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.04 Bn | 198.05 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.35 Bn | 178.17 Bn | 6.22 Bn | 600.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.22 Bn | 124.37 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.94 Bn | 74.94 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.53 Bn | 56.34 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.25 Bn | 49.11 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.41 Bn | 31.10 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.19 Bn | 29.91 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn | 1.39 Mn |
| 10 | Kiniksa Pharmaceuticals International | 6.12 Bn | 5.60 Bn | 220.03 Mn | -93,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -93,000.00 |
| Mar 31, 2026 | -1.30 Mn |
| Dec 31, 2025 | 930,000.00 |
| Sep 30, 2025 | -603,000.00 |
| Jun 30, 2025 | 844,000.00 |
| Mar 31, 2025 | -255,000.00 |
| Dec 31, 2024 | -819,000.00 |
| Sep 30, 2024 | 487,000.00 |
| Jun 30, 2024 | 188,000.00 |
| Mar 31, 2024 | -297,000.00 |
| Dec 31, 2023 | 296,000.00 |
| Sep 30, 2023 | -1.44 Mn |
| Jun 30, 2023 | 1.15 Mn |
| Mar 31, 2023 | 1.06 Mn |
| Dec 31, 2022 | 203,000.00 |
| Sep 30, 2022 | 119,000.00 |
| Jun 30, 2022 | -76,000.00 |
| Mar 31, 2022 | -164,000.00 |
| Dec 31, 2021 | -47,000.00 |
| Sep 30, 2021 | -14,000.00 |